Supplementary Data — Deuremidevir for COVID-19: real-time meta-analysis of 2 studies

@CovidAnalysis, October 2026, Version 1V1

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Deuremidevir COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Shen11%0.89 · 0.79–1.01viral time60 (n)76 (n) Shen23%0.77 · 0.66–0.90viral time32 (n)76 (n) Shen−3%1.03 · 0.89–1.19viral time28 (n)76 (n) Fan (DB RCT)67%0.33 · 0.01–8.18severe case0/6461/650 Fan (DB RCT)15%0.85 · 0.75–0.96recovery646 (n)650 (n) Fan (DB RCT)14%0.86 · 0.70–1.05no recov.133/646156/650 Fan (DB RCT)24%0.76 · 0.63–0.93viral load99 (n)107 (n)

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Deuremidevir
reduces riskDeuremidevir
increases risk →

Fig. S1. All outcomes.

Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.